GlassScriptPhysician profile
Jillian Beth Doan
NPI 1922785955
$1,950.73
in general payments reported to CMS, 2019-2025
32 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $155 · 2024: $1,243 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.76 | 2024-2025 | |
| Janssen Biotech, INC. | $220.71 | 2024-2025 | Tremfya, Stelara |
| Harmony Biosciences LLC | $188.23 | 2023-2025 | Wakix |
| Celgene Corporation | $112.11 | 2024 | Zeposia |
| Baxter Healthcare | $99.85 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $75.35 | 2024-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $71.29 | 2023-2025 | Eohilia, Entyvio |
| Aimmune Therapeutics, INC. | $69.53 | 2024-2025 | Zenpep |
| Grifols USA, LLC | $67.02 | 2023-2025 | Xembify |
| Merck Sharp & Dohme LLC | $62.82 | 2024 | Dificid, Pifeltro, Delstrigo |
| Genzyme Corporation | $57.81 | 2024 | |
| Melinta Therapeutics, LLC | $57.03 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Intercept Pharmaceuticals, INC. | $50.18 | 2023-2024 | Ocaliva |
| Integra Lifesciences Corporation | $47.89 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ipsen Biopharmaceuticals, INC | $46.58 | 2024-2025 | Iqirvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.12 | 2023-2024 | Airsupra |
| United Therapeutics Corporation | $44.62 | 2023-2024 | Tyvaso |
| Qol Medical, LLC | $38.20 | 2023-2025 | Sucraid |
| Pfizer INC. | $35.91 | 2023-2024 | |
| Mylan Specialty L.P. | $30.26 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $24.63 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $23.01 | 2024 | Dupixent |
| Radius Health, INC. | $22.02 | 2025 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $19.93 | 2025 | |
| Organon LLC | $18.48 | 2024 | |
| Ardelyx, INC. | $17.86 | 2025 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $17.79 | 2024 | Monoferric |
| Lilly USA, LLC | $16.40 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $16.27 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.29 | 2023 | Xifaxan |
| Avadel Cns Pharmaceuticals, LLC | $15.07 | 2024 | Lumryz |
| Viatris Specialty LLC | $13.71 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.